Oncologic Drugs Advisory Committee

December 5, 2007

BRIEFING INFORMATION

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Material (pdf)

Addendum (pdf)

Genentech, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

AVASTIN (Bevacizumab), Genentech, Inc.

Briefing Material (pdf)